title: [Focal segmental glomerulosclerosis].
abstract: Focal segmental glomerulosclerosis (FSGS) is one of the major causes of nephrotic syndrome in adult as well as in the children. Untreated or steroid-resistant primary FSGS often shows a progressive renal insufficiency and reaches to end-stage renal failure. Concerning the treatment for such patients, the combined immunosuppressive therapy with corticosteroid and other cytotoxic drugs (cyclophosphamide, cyclosporine and tacrolimus etc.) is recommended. Since podocyte injury seems to be the most important primary events in FSGS, the extensive studies have been focused on the role of podocyte-related molecules. Recently slit membrane-associated molecules (CD2AP, alpha-actinin 4 and podocin) and angiotensin II type I receptor in the podocyte have been clearly shown to be relevant for the pathogenesis of FSGS.
authors.affiliation: Clinical Immunology, Department of Internal Medicine, Nagoya University Graduate School of Medicine.
authors.forename: Yukio
authors.initials: Y
authors.lastname: Yuzawa
authors.forename: Seiichi
authors.initials: S
authors.lastname: Matsuo
mesh_terms: D000185:Actinin / Q000502:physiology; D048868:Adaptor Proteins, Signal Transducing; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D000818:Animals; D002244:Carbon / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D016572:Cyclosporine / Q000008:administration & dosage; D003598:Cytoskeletal Proteins; D005923:Glomerulosclerosis, Focal Segmental / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007164:Immunosorbents / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D047908:Intracellular Signaling Peptides and Proteins; D007678:Kidney Glomerulus / Q000166:cytology* / Q000473:pathology; D008565:Membrane Proteins / Q000502:physiology; D008840:Microfilament Proteins / Q000502:physiology; D010087:Oxides / Q000008:administration & dosage; D010951:Plasma Exchange; D011239:Prednisolone / Q000008:administration & dosage; D011506:Proteins / Q000502:physiology; D044140:Receptor, Angiotensin, Type 1 / Q000502:physiology; D025721:WT1 Proteins / Q000502:physiology
chemical_list: C491751:Actn4 protein, rat; D048868:Adaptor Proteins, Signal Transducing; D000806:Angiotensin-Converting Enzyme Inhibitors; C114545:CD2-associated protein; D003598:Cytoskeletal Proteins; D007164:Immunosorbents; D007166:Immunosuppressive Agents; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D008840:Microfilament Proteins; C407223:NPHS2 protein; D010087:Oxides; D011506:Proteins; D044140:Receptor, Angiotensin, Type 1; D025721:WT1 Proteins; D000185:Actinin; D002244:Carbon; D016572:Cyclosporine; D003520:Cyclophosphamide; C040896:AST 120; D011239:Prednisolone